论文部分内容阅读
SN411（fluticasonepropionate，FP）系英国葛兰素公司开发的新合成副肾皮质类固醇，因在肝脏被迅速代谢失活，难以作用于全身，仅适用于局部疗法。FP的人血管收缩作用强，约为declomethasonebipropionate（BDP）的2倍。以BDP每日4次，每次1000μg为对照，采用电话登记法对FP吸
SN411 (fluticasonepropionate, FP) is a newly synthesized paranalcorticoid steroid developed by GlaxoSmithKline in the United Kingdom. It is hard to act on the body due to rapid metabolism in the liver and is only suitable for local therapy. The vasoconstrictor effect of FP is strong, about twice that of declomethasonebipropionate (BDP). BDP 4 times a day, each 1000μg as a control, using the telephone registration method FP suction